Genentech announces updated data from Venclexta® clinical trials
Category: #health  By Pankaj Singh  Date: 2019-12-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Genentech announces updated data from Venclexta® clinical trials

Chronic lymphocytic leukemia (CLL) is a common type of adult leukemia. In the United States, it is estimated that more than 20,000 new cases of CLL will be diagnosed in 2019. With an eye to cure CLL, biotechnology company Genentech, Inc. has recently announced updated data from two pivotal Phase 3 Venclexta® clinical trials (CLL14 and MURANO).

The studies highlight that Venclexta combination therapies as chemotherapy-free, fixed-duration option that achieved MRD (minimal residual disease)-negativity, in people with CLL. Reportedly, Phase 3 CLL14 study accessed the combination of Venclexta plus Gazyva® (obinutuzumab) in untreated CLL patients, who had co-existing medical conditions.

At a median follow-up of over three years, when all patients had been off therapy for more than 24 months, Venclexta plus Gazyva demonstrated high response rates, comprising MRD-negativity.

In an updated analysis of CLL14, the chemotherapy-free, fixed-duration of Venclexta plus Gazyva combination reduced the chances of disease worsening by 69% in comparison with Gazyva plus chlorambucil. Moreover, it attained remissions that were stable over time in patients with untreated CLL.

The Phase III MURANO trial meanwhile evaluated Venclexta plus Rituxan® (rituximab) combination in relapsed or refractory CLL. After a 4-year follow-up, the combination showed positive activity by lowering disease progression as compared to a standard of care therapy in previously treated CLL. 

According to Levi Garraway, M.D., Ph.D., CMO, and Head of Global Product Development, Roche, Venclexta with anti-CD20 monoclonal antibody-based regimens is continuously showing improved long terms results for people who are suffering from CLL. These updated analyses reinforced the sustained clinical benefits observed in patients with CLL, after completing chemotherapy-free, fixed duration treatment. 

Reliable reports cite that Venclexta is being developed by Genentech and AbbVie. It is jointly commercialized by both companies in the U.S. and commercialized by AbbVie abroad. Meanwhile, the data from Venclexta clinical development program will be presented in over 50 abstracts at 61st ASH (American Society of Hematology) annual meet. 

Source Credit - https://www.gene.com/media/press-releases/14829/2019-12-08/new-data-demonstrate-the-continued-clini

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Samsung rolls out its expanded 2021 Odyssey gaming monitor range
Samsung rolls out its expanded 2021 Odyssey gaming monitor range
By Pankaj Singh

Samsung Electronics, one of the leading players in the gaming monitor market, has reportedly announced the commercial launch of its expanded 2021 lineup of Odyssey gaming monitor. Following the launch of its curve-shaped gaming monitor in 2020, the c...

Indonesia to only sell electric motorcycles and vehicles by 2050
Indonesia to only sell electric motorcycles and vehicles by 2050
By Pankaj Singh

The country is seeking to increase the processing of nickel laterite ore which is used in lithium batteries In a bid to reduce carbon emission levels, the Energy Minister of Indonesia, Arifin Tasrif has announced that the nation is planning to only ...

Amway announces Rs 170 crore investment in India over 2-3 years
Amway announces Rs 170 crore investment in India over 2-3 years
By Pankaj Singh

Nutraceuticals giant, Amway, has reportedly made it to the front page following its recent announcement of investing a whopping Rs 170 crore in the Indian sub-continent over the next 2 to 3 years, in an attempt to boost the research and development, ...